title: [Sepsis in hemato-oncologic patients].
abstract: The general approach regarding the treatment of sepsis in patients with oncological or haematological malignancies does not differ significantly from that in immunocompetent individuals, however, there are several specialities. The main causes of severe infections in cancer patients include deranged cellular or humoral immunity due to the underlying disease, severe neutropenia as a consequence of cytostatic regimens, lesions of the mucosal barriers due to adverse effects of antineoplastic agents, and violations of the integument by therapeutic interventions. Due to the impaired host defense, life threatening infections can occur more often in these patients, thereby limiting the benefits of antineoplastic therapy. On this account precise and intensive therapy has to be initiated in the early stages of sepsis. In the following, we will not primarily focus on sepsis specific treatment modalities, but merely try to elucidate in more detail the pathomechanisms and special features with regard to infectious complications and specific treatment.
authors.affiliation: Intensivstation 13i2, Universitätsklinik für Innere Medizin I, Währinger Gürtel 18-20, A-1090 Wien. gottfried.locker@akh-wien.ac.at
authors.forename: G J
authors.initials: GJ
authors.lastname: Locker
authors.forename: T
authors.initials: T
authors.lastname: Staudinger
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects; D003422:Critical Care; D019337:Hematologic Neoplasms / Q000276:immunology*; D006801:Humans; D009369:Neoplasms / Q000276:immunology*; D009503:Neutropenia / Q000276:immunology; D009894:Opportunistic Infections / Q000276:immunology* / Q000628:therapy; D011379:Prognosis; D012772:Shock, Septic / Q000276:immunology* / Q000628:therapy
chemical_list: D000970:Antineoplastic Agents